Literature DB >> 20816372

Safety of denosumab in giant-cell tumour of bone.

David Thomas, Phillipe Carriere, Ira Jacobs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20816372     DOI： 10.1016/S1470-2045(10)70170-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

Review 1.  Role of genetic and molecular profiling in sarcomas.

Authors:  Scott M Norberg; Sujana Movva
Journal:  Curr Treat Options Oncol       Date:  2015-05

2.  Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.

Authors:  Shinji Tsukamoto; Andreas F Mavrogenis; Giulio Leone; Alberto Righi; Manabu Akahane; Piergiuseppe Tanzi; Akira Kido; Kanya Honoki; Yasuhito Tanaka; Davide Maria Donati; Costantino Errani
Journal:  Int Orthop       Date:  2018-08-11       Impact factor: 3.075

Review 3.  Denosumab and giant cell tumour of bone-a review and future management considerations.

Authors:  S F Xu; B Adams; X C Yu; M Xu
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

Review 4.  Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.

Authors:  Aneta Maria Borkowska; Anna Szumera-Ciećkiewicz; Bartłomiej Szostakowski; Andrzej Pieńkowski; Piotr Lukasz Rutkowski
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

5.  Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts.

Authors:  Tobias Lange; Christoph Stehling; Birgit Fröhlich; Mark Klingenhöfer; Philip Kunkel; Reinhard Schneppenheim; Gabriele Escherich; Georg Gosheger; Jendrik Hardes; Heribert Jürgens; Tobias L Schulte
Journal:  Eur Spine J       Date:  2013-03-01       Impact factor: 3.134

6.  Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.

Authors:  Socrates Papapoulos; Roland Chapurlat; Cesar Libanati; Maria Luisa Brandi; Jacques P Brown; Edward Czerwiński; Marc-Antoine Krieg; Zulema Man; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; José A Román Ivorra; Christian Roux; Eric Vittinghoff; Matthew Austin; Nadia Daizadeh; Michelle N Bradley; Andreas Grauer; Steven R Cummings; Henry G Bone
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

7.  Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).

Authors:  Andrés Redondo; Silvia Bagué; Daniel Bernabeu; Eduardo Ortiz-Cruz; Claudia Valverde; Rosa Alvarez; Javier Martinez-Trufero; Jose A Lopez-Martin; Raquel Correa; Josefina Cruz; Antonio Lopez-Pousa; Aurelio Santos; Xavier García Del Muro; Javier Martin-Broto
Journal:  Cancer Chemother Pharmacol       Date:  2017-10-16       Impact factor: 3.333

8.  The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.

Authors:  Henry G Bone; Roland Chapurlat; Maria-Luisa Brandi; Jacques P Brown; Edward Czerwinski; Marc-Antoine Krieg; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; Jose A Román Ivorra; Christian Roux; Eric Vittinghoff; Nadia S Daizadeh; Andrea Wang; Michelle N Bradley; Nathalie Franchimont; Michelle L Geller; Rachel B Wagman; Steven R Cummings; Socrates Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.